Stone Crest Wealth Management, Inc. Viridian Therapeutics, Inc.\De Transaction History
Stone Crest Wealth Management, Inc.
- $157 Billion
- Q1 2025
A detailed history of Stone Crest Wealth Management, Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Stone Crest Wealth Management, Inc. holds 25,707 shares of VRDN stock, worth $373,265. This represents 0.22% of its overall portfolio holdings.
Number of Shares
25,707
Previous 25,859
0.59%
Holding current value
$373,265
Previous $496 Million
30.1%
% of portfolio
0.22%
Previous 0.32%
Shares
6 transactions
Others Institutions Holding VRDN
# of Institutions
189Shares Held
79.6MCall Options Held
92.2KPut Options Held
55.2K-
Deep Track Capital, LP Greenwich, CT5.38MShares$78.1 Million2.54% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$69.3 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.7MShares$68.2 Million5.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.56MShares$66.3 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$56.4 Million12.64% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $579M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...